CD80, suPAR and Nephrotic Syndrome in a case of NPHS2 mutation

Gabriel Cara-Fuentes, Carlos Araya, Changli Wei, Christopher Rivard, Takuji Ishimoto, Jochen Reiser, Richard J. Johnson, Eduardo H. Garin

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Background: Podocin mutations are characterized by progression to end stage renal disease and histologic findings of Focal Segmental Glomerulosclerosis (FSGS). CD80 is a podocytes protein that may play a role in proteinuria, particularly in Minimal Change Disease whereas the soluble urokinase receptor (suPAR) is characteristically elevated in the serum of FSGS patients. Methods: In a patient with nephrotic syndrome and podocin mutation, urinary and serum CD80 as well as suPAR were measured using commercially available kits. Urinary CD80 molecular size was determined by western blot analysis. Glomerular staining for CD80 and podocin was performed. Results: Patient displayed marked elevated CD80 and mildly increased suPAR urinary levels compared to controls. Serum CD80 level was within the range observed in normal controls. Serum su- PAR level was elevated, albeit in the lower range reported for patients with primary FSGS. Immunofluorescence examination of kidney biopsy revealed glomerular CD80 expression. Conclusion: The combination of serum and urinary biomarkers can help differentiate various forms of FSGS. High urinary CD80 and elevated serum and urinary suPAR might represent a profile to differentiate this genetic form of FSGS from primary FSGS.

Original languageEnglish (US)
Pages (from-to)727-731
Number of pages5
Issue number5
StatePublished - 2013
Externally publishedYes


  • CD80
  • Nephrotic syndrome
  • Podocin mutation
  • Podocyte
  • Supar

ASJC Scopus subject areas

  • Nephrology


Dive into the research topics of 'CD80, suPAR and Nephrotic Syndrome in a case of NPHS2 mutation'. Together they form a unique fingerprint.

Cite this